{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2011"],"data_sharing_plan":["IPD Sharing (as of July 2017): No\nDescription: There is no plan for this"],"condition":["Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2118178"],"location":["United States"],"study_start_month":["12"],"keyword":["Bortezomib","Panitumumab","Kras wild type"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer","description":"Panitumumab plus bortezomib for colon cancer","dates":{"creation":"2011-12-15"},"accession":"2118178","cross_references":{"ClinicalTrials___gov":["NCT01504477"]}}